Provention Bio Gets Patent Approval for Coxsackievirus B Vaccine to Prevent; Treat Type 1 Diabetes

Published on
By : dLife Editors

Provention Bio, Inc., a company aimed at intercepting and preventing immune-mediated diseases, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application for coxsackievirus B (CVB) vaccine to prevent or treating type 1 diabetes.

Provention Bio is developing PRV-101 as a vaccine for acute coxsackie virus infection and potentially as the first-ever vaccine designed to prevent T1D.

Epidemiological and experimental studies indicate that approximately half of all T1D cases could be triggered by a CVB infection in early childhood.

Based on this research, which was recently the subject of a peer-reviewed paper in Expert Review of Vaccines, Provention Bio is developing PRV-101 to reduce the onset of T1D by vaccinating at-risk populations against CVB infection.

PRV-101 is currently in an IND-enabling stage prior to the initiation of first-in-human studies.

“This Notice of Allowance from the USPTO is a significant advancement in the ongoing development of PRV-101 and emboldens Provention’s vision to develop a vaccine for CVB that could potentially prevent up to 50% of worldwide T1D cases,” said Ashleigh Palmer, Provention Bio’s Co-Founder and Chief Executive Officer.  “As we advance PRV-101 towards the clinic, we will continue to aggressively pursue opportunities to strengthen the intellectual property estate surrounding this technology and the use of a polyvalent CVB vaccine to prevent T1D,” he added.

For more information on Provention Bio, please visit


  1. Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D). (2019, Jan. 29). Retrieved from